EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Efficacy and Safety of Baxdrostat in Resistant or Uncontrolled Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Mohammed Saeed Ali Al-Zahrani, Abdullah Naser Alotibi, Jory A. Khojah, Shahad M. AlQurashi, Lamees F Alharbi, Sarah Ahmed Alamoudi, Fatimah Ahmed Alsinan, Eman Ahmed Alsaif, Hadeel Falah Almutairi, Nada Adel Alghamdi, Abdullah Saleh Almithn, Khaled Waleed Al Assiri und 3 weitere

Cureus · 18.11.2026

DOI: 10.7759/cureus.119883 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Cureus, erschienen am 18.11.2026. Verfasst von Mohammed Saeed Ali Al-Zahrani und 14 weiteren Autor:innen. Die Arbeit nennt 27 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Baxdrostat is a selective aldosterone synthase inhibitor developed for uncontrolled and resistant hypertension. This systematic review and meta-analysis evaluated the efficacy and safety of baxdrostat in randomized trials. The review was reported in accordance with PRISMA guidance. PubMed, Scopus, Web of Science, and the Cochrane Library were searched through March 2026 for randomized controlled trials comparing baxdrostat with placebo in adults with uncontrolled or resistant hypertension. Quantitative synthesis used a random-effects model, and certainty of evidence was assessed using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) framework. Three RCTs comprising 1,285 participants in the treated/modified intention-to-treat populations were included. Baxdrostat reduced office systolic blood pressure (MD = -9.06 mmHg; 95% CI: -11.03 to -7.09; P < 0.01), office diastolic blood pressure (MD = -3.62 mmHg; 95% CI: -4.86 to -2.38; P < 0.0001), and 24-hour ambulatory systolic blood pressure (MD = -14.27 mmHg; 95% CI: -17.13 to -11.41; P < 0.01). Any adverse events occurred in 46.5% of baxdrostat-treated versus 40.0% of placebo participants (RR = 1.17; 95% CI: 1.02 to 1.33), while hyperkalemia occurred in 4.9% versus 0.2% (RR = 9.39; 95% CI: 2.23 to 39.57). Baxdrostat was associated with short-term reductions in office and ambulatory blood pressure in the included randomized trials. Hyperkalemia and changes in renal function remain clinically relevant safety considerations, and longer-term studies are needed to define its durability, renal safety, and effects on cardiovascular outcomes.

Zitieren

APA

Al-Zahrani, M. S. A., Alotibi, A. N., Khojah, J. A., AlQurashi, S. M., Alharbi, L. F., Alamoudi, S. A., Alsinan, F. A., Alsaif, E. A., Almutairi, H. F., Alghamdi, N. A., Almithn, A. S., Assiri, K. W. A., Alsharif, I. M., Otman, M. A., & Alshahrani, H. S. H. (2026). Efficacy and Safety of Baxdrostat in Resistant or Uncontrolled Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cureus. https://doi.org/10.7759/cureus.119883

Vancouver

Al-Zahrani MSA, Alotibi AN, Khojah JA, AlQurashi SM, Alharbi LF, Alamoudi SA, et al. Efficacy and Safety of Baxdrostat in Resistant or Uncontrolled Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cureus. 2026. doi:10.7759/cureus.119883

BibTeX
@article{AlZahrani2026,
  author = {Al-Zahrani, Mohammed Saeed Ali and Alotibi, Abdullah Naser and Khojah, Jory A. and AlQurashi, Shahad M. and Alharbi, Lamees F and Alamoudi, Sarah Ahmed and Alsinan, Fatimah Ahmed and Alsaif, Eman Ahmed and Almutairi, Hadeel Falah and Alghamdi, Nada Adel and Almithn, Abdullah Saleh and Assiri, Khaled Waleed Al and Alsharif, Ibrahim Majed and Otman, Mohamad A. and Alshahrani, Hussein Saeed H.},
  title = {Efficacy and Safety of Baxdrostat in Resistant or Uncontrolled Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials},
  journal = {Cureus},
  year = {2026},
  doi = {10.7759/cureus.119883}
}
Kostenlos starten →